CJC-1295 with DAC vs Mod GRF 1-29 (No DAC): Same Peptide Core, Two Pharmacokinetic Profiles

CJC-1295 and Mod GRF 1-29 are not two different drugs in the pharmacological sense — they are the same tetrasubstituted GRF(1-29) peptide with and without a half-life extension technology. Both are agonists of the pituitary GHRH receptor (GHRHR), a Gs-coupled receptor on somatotroph cells whose activation raises intracellular cAMP and drives synthesis and release of growth hormone. Both act upstream of GH rather than replacing it, so both require an intact pituitary and preserve endogenous feedback control by somatostatin.

The shared core carries four amino acid substitutions engineered for enzymatic stability, the best characterized being D-Ala at position 2. Native GRF(1-29) is inactivated within minutes when the enzyme DPP-IV cleaves it at the Ala2-Asp3 bond; the D-isomer substitution makes the peptide a poor substrate. In a controlled infusion study in 10 normal men, the D-Ala2 analog's metabolic clearance fell from 39.7 ± 3.9 to 21 ± 1.2 mL/kg/min (P<0.001), and its disappearance half-time lengthened from 4.3 to 6.7 minutes (PMID: 7962295). This stabilization is real but modest — it is why both molecules resist DPP-IV, and also why further engineering was pursued.

What the DAC adds: CJC-1295 carries a maleimidopropionyl group on a C-terminal lysine that covalently bioconjugates to the Cys34 thiol of serum albumin within minutes of injection, creating a circulating drug reservoir. The ConjuChem identification study showed all such bioconjugates retained GRF receptor activation on rat anterior pituitary cells with enhanced DPP-IV stability, and the lead compound CJC-1295 produced a 4-fold greater GH area under the curve than unmodified hGRF(1-29) in rats while remaining detectable in plasma beyond 72 hours (PMID: 15817669).

The mechanistic conclusion is stark: receptor pharmacology is identical; exposure duration is everything that differs. For research interpretation, this means any pharmacodynamic difference reported between the two forms must trace to kinetics — peak concentration, receptor occupancy time, or pulse architecture — not to the peptide sequence itself, and any claim of distinct biological effects between the two molecules on mechanistic grounds should be read skeptically.

The pharmacokinetic gap between these two forms is among the largest achievable by a single chemical modification in peptide therapeutics.

CJC-1295 (DAC form): Two randomized, double-blind, placebo-controlled ascending-dose trials in healthy adults aged 21-61 established the human profile (PMID: 16352683):

• Half-life: Estimated 5.8-8.1 days after subcutaneous injection
• GH elevation: Dose-dependent mean GH increases of 2- to 10-fold lasting 6 days or more after a single dose
• IGF-1 elevation: 1.5- to 3-fold increases lasting 9-11 days; after multiple doses, IGF-1 remained above baseline for up to 28 days
• Best-tolerated doses: 30 or 60 µg/kg, supporting once-weekly administration in research protocols

Mod GRF 1-29 (no-DAC core): Without the linker, the peptide cannot bioconjugate and is cleared in minutes. The closest controlled human data come from the D-Ala2-GRF(1-29) infusion study: a disappearance half-time of 6.7 ± 0.5 minutes in normal men (PMID: 7962295). Rat studies in the ConjuChem program confirmed the pattern — the unconjugated tetrasubstituted analog produced only acute GH release, while conjugated CJC-1295 persisted in plasma beyond 72 hours (PMID: 15817669).

Practical consequence for research design: the no-DAC core requires multiple daily subcutaneous administrations to maintain any elevation, and each injection produces a discrete GHRH stimulus followed by rapid return to baseline. The DAC form produces continuous receptor occupancy from a single weekly injection. Any protocol claiming week-long activity for "CJC-1295 without DAC" conflates two pharmacokinetically distinct molecules — removing the DAC removes the long action that defines CJC-1295. The two forms also differ in what an experiment can measure: the no-DAC core permits classic acute dose-ranging within a single day with full washout between administrations, while the DAC form's week-long pharmacokinetic tail means carryover between doses must be designed around, with sampling schedules measured in days rather than minutes.

The central human study for this comparison is the Ionescu and Frohman pulsatility analysis (PMID: 17018654), because it answers the question most researchers ask about the DAC form: does continuous GHRH receptor stimulation abolish the body's pulsatile GH rhythm?

Design and findings: Healthy men aged 20-40 underwent 20-minute overnight blood sampling before and 1 week after a single CJC-1295 injection (60 or 90 µg/kg). Continuous GHRH receptor stimulation preserved GH pulsatility:

• Pulse frequency and magnitude: Unaltered after a week of continuous stimulation
• Basal (trough) GH: Rose 7.5-fold (P<0.0001)
• Mean GH: Rose 46% (P<0.01)
• IGF-1: Rose 45% (P<0.001)

The DAC form therefore amplifies endogenous secretion by raising the baseline between pulses rather than overriding the rhythm — a profile distinct from exogenous recombinant GH, which imposes a non-pulsatile level and suppresses endogenous secretion through negative feedback. This is the strongest evidence-based argument for GHRH-class analogs over direct GH administration in research.

The honest caveat for the no-DAC side: no published human clinical trial has evaluated Mod GRF 1-29 as a standalone compound. The human GH, IGF-1, and safety data commonly attributed to it derive from CJC-1295 studies of the same core in albumin-conjugated form (PMID: 16352683, PMID: 17018654) and from infusion studies of the singly substituted D-Ala2 analog (PMID: 7962295). Extrapolating week-long effects to the no-DAC peptide is not supported by any published data.

Research-design tradeoff: sustained elevation suits studies of IGF-1-mediated endpoints and body composition where stable exposure is desired; brief pulsatile stimulation suits hypothalamic-pituitary physiology work, feedback-loop studies, and designs that coordinate GHRH with ghrelin-receptor agonists to mimic the natural dual regulation of GH secretion.

CJC-1295 (human data): In the Phase 1 ascending-dose trials, no serious adverse reactions occurred, with best tolerability at 30 or 60 µg/kg (PMID: 16352683). Reported effects were consistent with the GHRH class: transient injection-site reactions, flushing, and dose-related effects expected from sustained GH/IGF-1 elevation. The Ionescu pulsatility study likewise reported the regimen as well tolerated over the observation period (PMID: 17018654).

Mod GRF 1-29 (no standalone human data): There is no dedicated human safety dataset for the no-DAC peptide. Its exposure profile — minutes per injection — limits cumulative drug exposure relative to the DAC form, but the safety of multiple daily administrations over weeks or months has never been characterized in a controlled setting. Safety claims circulating in research communities extrapolate from CJC-1295, which is a different exposure paradigm.

Shared theoretical considerations:

• Sustained IGF-1 elevation: Chronic elevation of IGF-1 is mitogenic in preclinical models; the long-term implications of weeks-long IGF-1 increases (PMID: 16352683) have never been studied in humans
• Feedback preservation: Because both molecules act upstream of GH, somatostatin-mediated negative feedback remains intact — unlike exogenous GH — but this does not eliminate concerns about prolonged receptor stimulation
• Regulatory status: Neither molecule is approved in any jurisdiction. CJC-1295 was an investigational ConjuChem program that never reached approval; the no-DAC core was never in formal clinical development. GHRH analogs and GH secretagogues as a class are prohibited in sport under the WADA Prohibited List (S2)
• Supply quality: Both are sold as research chemicals; identity and purity of gray-market material are unverified, a material risk factor in any experimental design

Long-term human safety is unestablished for both forms, and no comparative safety trial exists. The practical research implication is conservative exposure design and honest reporting of the evidence gap — particularly for protocols that extrapolate the conjugate's published safety profile to the unconjugated core, which is the weaker-evidence molecule of the pair.

CJC-1295 (DAC) suits research questions involving:

• Sustained GH and IGF-1 elevation over days from a single administration
• Protocols where once-weekly dosing is a design requirement
• Endpoints mediated by chronic IGF-1 exposure (body composition, protein metabolism)
• Any design requiring actual human pharmacokinetic and safety data — it is the only form with published RCTs (PMID: 16352683, PMID: 17018654)

Mod GRF 1-29 (no DAC) suits research questions involving:

• Pulsatile GHRH receptor stimulation with rapid return to baseline between doses
• Hypothalamic-pituitary feedback physiology, where continuous stimulation would confound the measurement
• Combination designs with ghrelin-receptor (GHSR-1a) agonists, where simultaneous short-acting administration produces a coordinated GH pulse mimicking natural dual regulation
• Dose-timing studies that require discrete, repeated stimulus windows

Unresolved questions: No head-to-head trial has ever compared the two forms in humans. Whether brief repeated GHRH pulses and sustained GHRH exposure differ in long-term receptor desensitization, somatotroph responsiveness, or downstream IGF-1 physiology is unknown; the Ionescu data (PMID: 17018654) show pulses persist under continuous stimulation, but say nothing about months of exposure. The no-DAC peptide's entire human profile is an extrapolation.

Terminology caution for the literature: "CJC-1295 without DAC" is not a long-acting product with a shorter label — it is Mod GRF 1-29, a different pharmacokinetic entity that was never the subject of the CJC-1295 clinical program. Citations of CJC-1295 human data should not be attributed to the no-DAC core without that qualification. Publications, vendor listings, and community protocols that use the two names interchangeably should be read with that substitution in mind, because the half-life difference — days versus minutes — changes every downstream interpretation of dose, frequency, and expected effect.